Public Meeting on Patient-Focused Drug Development for Chronic Pain

Public Meeting on Patient-Focused Drug Development for Chronic Pain

On July 9, 2018, FDA is hosting a public meeting on Patient-Focused Drug Development for Chronic Pain. FDA is interested in hearing patients’ perspectives on chronic pain, views on treatment approaches, and challenges or barriers to accessing treatments for chronic pain. FDA is particularly interested in hearing from patients who experience chronic pain that is managed with analgesic medications such as opioids, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), antidepressants; other medications; and non-pharmacologic interventions or therapies.

For more information and registration information, visit: Public Meeting on Patient-Focused Drug Development for Chronic Pain